These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9497862)

  • 1. Enzyme replacement therapy for Gaucher's disease.
    Beutler E
    Baillieres Clin Haematol; 1997 Dec; 10(4):751-63. PubMed ID: 9497862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First long-term results of imiglucerase therapy of type 1 Gaucher disease.
    Niederau C; vom Dahl S; Häussinger D
    Eur J Med Res; 1998 Feb; 3(1-2):25-30. PubMed ID: 9512964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A less costly regimen of alglucerase to treat Gaucher's disease.
    Figueroa ML; Rosenbloom BE; Kay AC; Garver P; Thurston DW; Koziol JA; Gelbart T; Beutler E
    N Engl J Med; 1992 Dec; 327(23):1632-6. PubMed ID: 1435900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.
    Whittington R; Goa KL
    Pharmacoeconomics; 1995 Jan; 7(1):63-90. PubMed ID: 10155294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alglucerase. A review of its therapeutic use in Gaucher's disease.
    Whittington R; Goa KL
    Drugs; 1992 Jul; 44(1):72-93. PubMed ID: 1379912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gaucher's disease: a review.
    Morales LE
    Ann Pharmacother; 1996 Apr; 30(4):381-8. PubMed ID: 8729893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replacement therapy with imiglucerase for type 1 Gaucher's disease.
    Zimran A; Elstein D; Levy-Lahad E; Zevin S; Hadas-Halpern I; Bar-Ziv Y; Foldes J; Schwartz AJ; Abrahamov A
    Lancet; 1995 Jun; 345(8963):1479-80. PubMed ID: 7769903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement In Symptoms Of Gaucher's Disease By Enzyme Replacement Therapy.
    Mazher W; Ali J; Abubakar S; Basar S; Murtaza G
    J Ayub Med Coll Abbottabad; 2018; 30(3):479-481. PubMed ID: 30465391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease.
    Hollak CE; Aerts JM; Goudsmit R; Phoa SS; Ek M; van Weely S; von dem Borne AE; van Oers MH
    Lancet; 1995 Jun; 345(8963):1474-8. PubMed ID: 7769902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imiglucerase and its use for the treatment of Gaucher's disease.
    Weinreb NJ
    Expert Opin Pharmacother; 2008 Aug; 9(11):1987-2000. PubMed ID: 18627336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Course of a case of Gaucher's disease type 1 treated over a year with glucocerebrosidase (Cérédase)].
    Belmatoug N; Azorin M; Huten D; de Villemeur TB; Carbon C
    Rev Med Interne; 1993; 14(10):996. PubMed ID: 8009089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of bone marrow failure in Gaucher's disease with low-dose modified glucocerebrosidase.
    Mistry PK; Davies S; Corfield A; Dixon AK; Cox TM
    Q J Med; 1992 Jul; 83(303):541-6. PubMed ID: 1484931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
    Cox TM; Drelichman G; Cravo R; Balwani M; Burrow TA; Martins AM; Lukina E; Rosenbloom B; Ross L; Angell J; Puga AC
    Lancet; 2015 Jun; 385(9985):2355-62. PubMed ID: 25819691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical outcomes of 2 pediatric patients with Gaucher's disease in enzyme replacement therapy for 9 years].
    Quijada Fraile P; Martín Hernández E; Teresa García-Silva M
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():43-5. PubMed ID: 22230125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
    Barton NW; Brady RO; Dambrosia JM; Di Bisceglie AM; Doppelt SH; Hill SC; Mankin HJ; Murray GJ; Parker RI; Argoff CE
    N Engl J Med; 1991 May; 324(21):1464-70. PubMed ID: 2023606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic targets in Gaucher's disease].
    Giraldo P; Roca M
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():46-9. PubMed ID: 22230126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gaucher's disease in pregnancy.
    Rosnes JS; Sharkey MF; Veille JC; Mueller-Heubach E
    Obstet Gynecol Surv; 1996 Sep; 51(9):549-58. PubMed ID: 8873155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gaucher's disease in Lithuania: its diagnosis and treatment.
    Kleinotienė G; Tylki-Szymanska A; Czartoryska B
    Medicina (Kaunas); 2011; 47(7):405-11. PubMed ID: 22112991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Persistence of pulmonary lesions in a 6-year-old boy with type I Gaucher's disease treated by alglucerase since the age of 20 months].
    Versteegh C; Avni F; Cuvelier P; Ferster A
    Arch Pediatr; 1998 Dec; 5(12):1341-3. PubMed ID: 9885741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease.
    Mistry PK; Wraight EP; Cox TM
    Lancet; 1996 Dec; 348(9041):1555-9. PubMed ID: 8950883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.